Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Merck & Co finalise vaccine alliance split

Dissolve Sanofi Pasteur MSD after poor sales growth

Sanofi Pasteur MSDMerck & Co and Sanofi have finalised the dissolution of their joint vaccines venture, Sanofi Pasteur MSD.

The former partners will now separately pursue vaccine development strategies for European patients, integrating their respective pipeline pursuits and products from the venture into their primary vaccines portfolios.

After over 20 years of business, the break-up came in the wake of poor growth, with Sanofi Pasteur MSD only bringing in sales of €824m in 2015 - less than a fifth of Sanofi's year-end vaccines sales of €4.7bn.

Each firm has a number of promising projects in the pipeline, with Sanofi and its vaccines unit Sanofi Pasteur focusing on vaccines for yellow fever, Japanese encephalitis and dengue virus.

The French company also began research for a potential Zika vaccine in February last year.

Meanwhile, Merck & Co (known as MSD outside of North America) is expected to launch its Ebola vaccine this year after a phase III trial of 4,000 patients saw 100% efficacy after a single dose.

World Health Organization vaccines specialist Marie Paule Kieny said that the trial results were a “game-changer” for patients and for fighting future outbreaks of the virus.

In a joint statement, Sanofi and Merck said: “We are proud of Sanofi Pasteur MSD's successful 20-year history.

“Our joint venture has achieved considerable success over the past two decades from a public health and commercial perspective.

“We believe that focusing our efforts on opportunities unique to our respective companies will better position us to drive growth, execute in a more efficient manner and optimise vaccine coverage.”

Article by
Rebecca Clifford

4th January 2017

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...